Table 4 Risk of prostate cancer death in a 1-year and 3-year lag-time analyses, when comparing users of AEDs to non-users and users of HDACi AEDs to users of other AEDs.

From: Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer

Risk of prostate cancer death

Anti-epileptic drug use compared to non-users

Use of HDACi AEDs compared to use of non-HDACi AEDs

1-year lag-time analysis

 

Number of PCa deaths/PCa cases

HR (95% CI)age adjusted

\({{{{{\mathbf{HR}}}}}} ({{{{{\mathbf{95\%}}}}}} {{{{{\mathbf{CI}}}}}})_{{{{{{\mathbf{multivariable}}}}}}\; {{{{{\mathbf{adjusted}}}}}}^{\mathbf a}}\)

 

Number of PCa deaths/PCa cases

HR (95% CI)age adjusted

\({{{{{\mathbf{HR}}}}}} ({{{{{\mathbf{95\%}}}}}} {{{{{\mathbf{CI}}}}}})_{{{{{{\mathbf{multivariable}}}}}}\; {{{{{\mathbf{adjusted}}}}}}^{\mathbf a}}\)

No use of AEDs

861/8665

Ref.

Ref.

Use of non-HDACi AEDs

37/318

Ref.

Ref.

Ever use of any AED

59/596

1.56 (1.08–2.24)

1.31 (0.90–1.92)

Ever use of HDACi AEDs

27/343

1.07 (0.48–2.40)

1.11 (0.49–2.53)

Intensity of usage (DDDs per year)

1st tertile

21/183

1.18 (0.44–3.16)

1.50 (0.56–4.01)

1st tertile

10/124

0.23 (0.03–1.82)

0.34 (0.04–2.68)

2nd tertile

22/216

1.93 (1.06–3.49)

1.49 (0.79–2.78)

2nd tertile

12/105

1.46 (0.58–3.70)

1.28 (0.49–3.31)

3rd tertile

16/197

1.48 (0.89–2.46)

1.17 (0.69–1.99)

3rd tertile

5/114

1.18 (0.47–2.92)

1.26 (0.50–3.19)

3-year lag-time analysis

No use of AEDs

861/8665

Ref.

Ref.

Use of non-HDACi AEDs

37/318

Ref.

Ref.

Ever use of any AED

59/596

1.80 (1.29–2.51)

1.55 (1.09–2.20)

Ever use of HDACi AEDs

27/343

1.50 (0.66–3.42)

1.44 (0.62–3.31)

Intensity of usage (DDDs per year)

1st tertile

21/183

1.52 (0.75–3.05)

2.02 (1.01–4.08)

1st tertile

10/124

1.12 (0.38–3.33)

1.43 (0.48–4.27)

2nd tertile

22/216

1.97 (1.11–3.48)

1.43 (0.76–2.67)

2nd tertile

12/105

1.71 (0.66–4.41)

1.28 (0.48–3.44)

3rd tertile

16/197

1.86 (1.13–3.04)

1.45 (0.87–2.43)

3rd tertile

5/114

1.58 (0.62–4.02)

1.59 (0.62–4.12)

  1. Study cohort of 9261 prostate cancer cases from the FinRSPC.
  2. aCalculated with Cox regression adjusted for age, simultaneous usage of other drugs (NSAIDs, aspirin, anti-diabetic drugs, anti-hypertensive drugs and statins), FinRSPC screening trial arm, Charlson co-morbidity score, prostate cancer risk group and primary treatment of PCa.
Back to article page